Whalen Wealth Management Inc. Invests $871,000 in Hims & Hers Health, Inc. $HIMS

Whalen Wealth Management Inc. acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 15,354 shares of the company’s stock, valued at approximately $871,000.

A number of other institutional investors also recently made changes to their positions in the stock. Virtus Advisers LLC purchased a new stake in shares of Hims & Hers Health in the second quarter valued at $26,000. Quaker Wealth Management LLC purchased a new stake in Hims & Hers Health during the 2nd quarter worth about $29,000. Bessemer Group Inc. raised its stake in Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after purchasing an additional 312 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in Hims & Hers Health in the 1st quarter valued at about $30,000. Finally, Hilltop National Bank acquired a new stake in shares of Hims & Hers Health during the 3rd quarter worth about $35,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Irene Becklund sold 8,411 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $308,767.81. Following the completion of the transaction, the insider owned 2,126 shares in the company, valued at $78,045.46. The trade was a 79.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Patrick Harrison Carroll sold 10,021 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $367,870.91. Following the completion of the transaction, the insider owned 169,940 shares of the company’s stock, valued at approximately $6,238,497.40. This trade represents a 5.57% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 233,429 shares of company stock worth $11,769,372. 13.71% of the stock is currently owned by insiders.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $34.74 on Friday. The business’s fifty day moving average price is $42.22 and its 200 day moving average price is $48.68. Hims & Hers Health, Inc. has a twelve month low of $23.97 and a twelve month high of $72.98. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The stock has a market capitalization of $7.91 billion, a P/E ratio of 64.33, a PEG ratio of 6.91 and a beta of 2.41.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). The firm had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business’s revenue was up 49.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.32 earnings per share. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health announced that its Board of Directors has authorized a stock buyback plan on Monday, November 17th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to reacquire up to 3% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

HIMS has been the topic of several recent analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday. KeyCorp began coverage on Hims & Hers Health in a research note on Tuesday, October 21st. They set a “sector weight” rating on the stock. UBS Group set a $32.00 price objective on Hims & Hers Health in a research report on Tuesday, November 4th. BTIG Research reiterated a “buy” rating and issued a $85.00 target price on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Finally, Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and an average price target of $45.50.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.